Search results for "Schedule"

showing 10 items of 567 documents

Early lipoic acid intake protects retina of diabetic mice

2008

The aim of this study was to test the effect of lipoic acid treatment on the retina after a short diabetic insult. Diabetes was induced by alloxan and mice were divided into sub-groups; control, diabetic, diabetic+insulin and all groups received+/-lipoic acid (100 mg/kg body weight) for 3 weeks. GSH content, MDA concentration, GPx activity were measured and electroretinograms (ERG) were recorded. Early administration of lipoic acid to diabetic mice prevented the statistically significant decreases of GSH content and GPx activity and normalized MDA concentration. Moreover, lipoic acid restored electroretinogram b-wave amplitude of diabetic animals to control values. Lipoic acid has a protect…

Malemedicine.medical_specialtyAntioxidantgenetic structuresmedicine.medical_treatmentmedicine.disease_causeBiochemistryAntioxidantsDrug Administration ScheduleRetinaDiabetes Mellitus ExperimentalMicechemistry.chemical_compoundMalondialdehydeInternal medicineDiabetes mellitusAlloxanElectroretinographymedicineAnimalsHypoglycemic AgentsInsulinGlutathione PeroxidaseDiabetic RetinopathyThioctic Acidbusiness.industryInsulinGeneral MedicineGlutathionemedicine.diseaseGlutathioneeye diseasesOxidative StressLipoic acidEndocrinologychemistrylipids (amino acids peptides and proteins)sense organsbusinessErgOxidative stressFree Radical Research
researchProduct

Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: Pleiotropic evidence from plasma mRNA analyses

2013

Objective: Statin pleiotropy is still an evolving concept, and the lack of clarity on this subject is due at least in part to the lack of a definitive biomarker for statin pleiotropy. Using plasma mRNA analysis as a novel research tool for the non-invasive in vivo assessment of gene expression in vascular beds, we hypothesised that atorvastatin lowers the plasmamRNA level from statin pleiotropy-target genes, and the reduction is independent of the reduction of low-density lipoprotein cholesterol (LDL-C). Design and methods: Forty-four patients with stable angina received atorvastatin therapy (20 mg/day, 10 weeks). Plasma chemokine (C-C motif) ligand 2 (CCL2) and intercellular adhesion molec…

Malemedicine.medical_specialtyChemokineStatinmedicine.drug_classAtorvastatinClinical BiochemistryGene ExpressionDrug Administration ScheduleIn vivoInternal medicineGene expressionAtorvastatinmedicineHumansPyrrolesAngina StableRNA MessengerSerum amyloid AChemokine CCL2AgedbiologyAnticholesteremic AgentsAtorvastatin CCL2 ICAM1 Interventional trial mRNA in plasma Pleiotropic effectsC-reactive proteinCholesterol LDLGeneral MedicineMiddle AgedIntercellular Adhesion Molecule-1EndocrinologyHeptanoic AcidsHMG-CoA reductasebiology.proteinFemalelipids (amino acids peptides and proteins)medicine.drugClinical Biochemistry
researchProduct

Association between Cognitive Performance and Cortical Glucose Metabolism in Patients with Mild Alzheimer’s Disease

2004

<i>Background:</i> Neuronal and synaptic function in Alzheimer’s disease (AD) is measured in vivo by glucose metabolism using positron emission tomography (PET). <i>Objective:</i> We hypothesized that neuronal activation as measured by PET is a more sensitive index of neuronal dysfunction than activity during rest. We investigated if the correlations between dementia severity as measured with the Mini Mental State Examination (MMSE) and glucose metabolism are an artifact of brain atrophy. <i>Method:</i> Glucose metabolism was measured using [<sup>18</sup>F]fluorodeoxyglucose PET during rest and activation due to audiovisual stimulation in 13 m…

Malemedicine.medical_specialtyCognitive NeuroscienceCentral nervous system diseaseCognitionDegenerative diseaseAtrophyAlzheimer DiseaseFluorodeoxyglucose F18Internal medicinemedicineHumansDementiaBrain atrophy;Partial volume effects;Alzheimer’s disease;Metabolism;Brain imaging techniquesAgedCerebral CortexMini–Mental State Examinationmedicine.diagnostic_testBrainMiddle Agedmedicine.diseaseddc:Psychiatry and Mental healthGlucoseEndocrinologyPositron emission tomographyPositron-Emission TomographyPosterior cingulateFemaleAtrophyGeriatrics and GerontologyAlzheimer's diseaseMental Status SchedulePsychologyDementia and Geriatric Cognitive Disorders
researchProduct

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?

2007

The on-treatment virological response to pegylated interferon plus ribavirin therapy is a useful tool in the management of patients with chronic hepatitis C. The time at which hepatitis C virus RNA becomes undetectable by a sensitive PCR assay has a huge impact on the probability of achieving a sustained virological response, particularly in genotype 1 patients, and may be useful in selecting patients for prolonged therapy. Indiscriminate extension of treatment in patients with hepatitis C virus genotype 1 is not beneficial. However, there is a subgroup of patients – the so-called ‘slow responders’ – who benefit from extending treatment from 48 to 72 weeks and can be readily identified afte…

Malemedicine.medical_specialtyCombination therapyGenotypeHepatitis C virusHepacivirusProlonged therapyHepacivirusInterferon alpha-2Chronic hepatitis Cmedicine.disease_causeGastroenterologyAntiviral AgentsDrug Administration SchedulePolyethylene Glycolschemistry.chemical_compoundInterferonPegylated interferonInternal medicineRibavirinmedicineHumansCombination therapyPeginterferonRapid virological responseViral kineticsExtended treatmentHepatologybiologybusiness.industryRibavirinPatient SelectionInterferon-alphaHepatitis C Chronicbiology.organism_classificationRecombinant ProteinsRegimenchemistryImmunologyRNA ViralDrug Therapy CombinationFemalebusinessPegylated interferonPeginterferon alfa-2amedicine.drugJournal of hepatology
researchProduct

High incidence of venous thrombosis after surgery for abdominal aortic aneurysm

2009

Objective The incidence of venous thromboembolism (VT) after aortic abdominal aneurysm (AAA) surgery is imprecisely reported. On one hand, thromboprophylaxis has improved, on the other hand, AAA patients have become older and/or present worse comorbidities. Herein, we prospectively analyzed the incidence of VT in a continuous series of patients operated on for AAA repair and looked for predictive factors. Materials and Methods Between January 1, 2005, and December, 31, 2006, 193 consecutive patients (177 men and 16 women), mean age 73 (range, 47-93) underwent elective AAA repair, 137 open (71%) and 56 endovascular (29%), in our institution. Thromboprophylaxis consisted of thigh-length compr…

Malemedicine.medical_specialtyDeep veinDrug Administration ScheduleAortic aneurysmRisk FactorsmedicineHumansProspective StudiesEnoxaparinEarly AmbulationAgedUltrasonographyAged 80 and overVenous Thrombosisbusiness.industryHeparinIncidenceAnticoagulantsTransfusion ReactionPerioperativeVenous ThromboembolismMiddle Agedmedicine.diseaseThrombosisAbdominal aortic aneurysmSurgeryVenous thrombosismedicine.anatomical_structureTreatment OutcomeAnesthesiaSurgeryFemaleFresh frozen plasmaCardiology and Cardiovascular MedicinebusinessVascular Surgical ProceduresStockings CompressionAbdominal surgeryAortic Aneurysm AbdominalJournal of Vascular Surgery
researchProduct

Management of Kidney Transplantation in a Factor VII-Deficient Patient: Case Report

2012

Transplantation in patients with congenital bleeding disorders is a challenge requiring an integrated approach of various specialists. Renal transplantation, the most frequent type of solid organ transplantation, is rarely performed in individuals with congenital hemorrhagic disorders. We performed a renal transplantation in a 53-year-old man with end-stage renal disease and congenital coagulation factor VII deficiency, a rare bleeding disorder with a peculiar clinical picture requiring replacement therapy in surgical interventions. Perioperative bleeding was successfully prevented by administration of recombinant activated factor VII. Treatment schedule, administration rate, and long-term …

Malemedicine.medical_specialtyDiseaseHemorrhagic disorderchemistry.chemical_compoundHumansMedicinekidney transplatation congenital bleeding disorders factor VII deficiency recombinant factor VII major surgerykidney transplantation inherited coagulation disorderCoagulation factor VIIKidney transplantationTransplantationFactor VIIbusiness.industryPerioperativeMiddle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationchemistryTreatment ScheduleFeasibility StudiesKidney Failure ChronicSurgerybusiness
researchProduct

The treatment of venous leg ulcers: a new therapeutic use of iloprost

2007

Background: We conducted a study using an intravenous (i.v.) infusion of iloprost in the treatment of venous ulcers to verify whether the association of i.v. iloprost + local therapy + elastic compression has a favorable effect when compared with traditional treatment with local therapy and elastic compression. Study Design: We evaluated the effects of iloprost in 98 consecutive patients with noncomplicated venous ulcers of lower limbs subdivided into 2 groups: the first group (48 patients) received iloprost in saline solution for 3 weeks and the second group (50 patients) received a venous infusion of a saline solution. The patients were examined at baseline time 0 (first visit) and then a…

Malemedicine.medical_specialtyElastic compressionmedicine.medical_treatmentIschemiaPlacebo groupDrug Administration Schedulelaw.inventionRandomized controlled triallawmedicineHumansSingle-Blind MethodIloprostInfusions IntravenousVeinSalineDose-Response Relationship Drugbusiness.industryvenous ulcersiloprostLeg UlcerSignificant differenceMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureDebridementAnesthesiaAnti-Infective Agents LocalFemaleSurgeryVENOUS LEG ULCERS ILOPROSTbusinessPlatelet Aggregation InhibitorsStockings CompressionIloprostmedicine.drug
researchProduct

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes

2010

AIM Postprandial release of intact proinsulin (IP) is an independent marker for beta-cell dysfunction in patients with type 2 diabetes. This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing metformin. MATERIAL AND METHODS Overall, 28 insulin-naive type 2 diabetes subjects (mean +/- SD age, 61.5 +/- 6.7 years; diabetes duration, 9.8 +/- 6.5 years; HbA1c, 7.1 +/- 0.5%; BMI, 30.7 +/- 4.3 kg/m(2)) treated with metformin and sulfonylurea were randomized to add once-daily GLA or NPH at bedtime. At baseline and after 3 months, subjects received a standardized breakfast, lunch and dinner, with pre- …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentInsulin IsophaneInsulin GlarginePilot ProjectsNPH insulinType 2 diabetesNPH insulinDrug Administration ScheduleEndocrinologyInsulin-Secreting CellsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinintact proinsulinGlycated Hemoglobinbusiness.industryInsulin glargineInsulindigestive oral and skin physiologynutritional and metabolic diseasesFastingOriginal ArticlesMiddle AgedPostprandial Periodmedicine.diseaseMetforminMetforminInsulin Long-ActingEndocrinologyPostprandialDiabetes Mellitus Type 2beta cell stressDrug Therapy CombinationFemalebusinessmedicine.drugBlood samplingDiabetes, Obesity and Metabolism
researchProduct

Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered sep…

2003

The safety and reactogenicity of a booster dose of GSK Biologicals' hexavalent DTPa-HBV-IPV/Hib vaccine (N=4725) was compared with the separate administration of GSK Biologicals' DTPa-IPV/Hib and HBV vaccines (N=4474) in two open, randomized multicenter studies (A and B). Solicited symptoms occurring within 4 days of vaccination were recorded on diary cards and serious adverse events (SAEs) were collected throughout the study period. In Study A (N=1149), incidences of solicited symptoms were similar in both groups; there were no SAEs either reported within 4 days of vaccination or considered to be causally related to vaccination. In study B (N=8050), where fever was the only solicited sympt…

Malemedicine.medical_specialtyFeverImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesInternal medicineConfidence IntervalsHumansMulticenter Studies as TopicMedicineHepatitis B VaccinesVaccines CombinedAdverse effectDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicHepatitis B virusBooster (rocketry)ReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunizationImmunologyMolecular MedicineFemalebusinessVaccine
researchProduct

Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study

2016

Introduction Pharmacokinetic (PK) studies on recombinant FIX concentrate, Nonacog alpha, were conducted with different sampling time designs which gave rise to not complete and homogenous outcomes. In addition, patient's FIX genotype/PK relationship has never been investigated. Aim Investigate how different sampling times may affect PK parameters and try to find a FIX genotype/PK relationship. Patients and Methods A cohort pharmacokinetic, Nonacog Alpha single-dose, open-label, non-comparative study was conducted in eight Comprehensive Care Haemophilia Centres in Italy. Seventeen previously treated moderate or severe haemophilia B patients were enrolled. Factors IX:C one-stage clotting assa…

Malemedicine.medical_specialtyGenotypeMutation MissensePharmacokinetic030204 cardiovascular system & hematologyPharmacologyHaemophiliaGastroenterologyHemophilia BDrug Administration ScheduleCohort StudiesFactor IX03 medical and health sciences0302 clinical medicinePharmacokineticsDNA Recombinant proteinInternal medicineHaemophilia BGenotypemedicineHumansHaemophilia BGenetics (clinical)Volume of distributionClotting factorbusiness.industryCoagulantsArea under the curveGeneral MedicineHematologymedicine.diseaseRecombinant ProteinsItalyROC CurveCodon NonsenseArea Under Curvebusinesspharmacokinetics030215 immunologyBlood samplingHalf-Life
researchProduct